FSD Pharma (HUGE) Competitors

$0.32
0.00 (0.00%)
(As of 05/17/2024 ET)

HUGE vs. PIRS, EDSA, RDHL, PPBT, KPRX, TNXP, ERNA, IMNN, NRSN, and AKTX

Should you be buying FSD Pharma stock or one of its competitors? The main competitors of FSD Pharma include Pieris Pharmaceuticals (PIRS), Edesa Biotech (EDSA), RedHill Biopharma (RDHL), Purple Biotech (PPBT), Kiora Pharmaceuticals (KPRX), Tonix Pharmaceuticals (TNXP), Eterna Therapeutics (ERNA), Imunon (IMNN), NeuroSense Therapeutics (NRSN), and Akari Therapeutics (AKTX). These companies are all part of the "pharmaceutical preparations" industry.

FSD Pharma vs.

FSD Pharma (NASDAQ:HUGE) and Pieris Pharmaceuticals (NASDAQ:PIRS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership, community ranking and earnings.

FSD Pharma has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Pieris Pharmaceuticals has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500.

FSD Pharma has a net margin of 0.00% compared to Pieris Pharmaceuticals' net margin of -39.71%. Pieris Pharmaceuticals' return on equity of -52.88% beat FSD Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
FSD PharmaN/A -70.35% -52.56%
Pieris Pharmaceuticals -39.71%-52.88%-27.85%

FSD Pharma has higher earnings, but lower revenue than Pieris Pharmaceuticals. FSD Pharma is trading at a lower price-to-earnings ratio than Pieris Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FSD PharmaN/AN/A-$17.90M-$0.26-1.23
Pieris Pharmaceuticals$42.81M0.34-$24.54M-$11.95-0.92

1.2% of FSD Pharma shares are owned by institutional investors. Comparatively, 40.1% of Pieris Pharmaceuticals shares are owned by institutional investors. 8.5% of FSD Pharma shares are owned by company insiders. Comparatively, 8.9% of Pieris Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
FSD Pharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Pieris Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Pieris Pharmaceuticals received 278 more outperform votes than FSD Pharma when rated by MarketBeat users. Likewise, 61.50% of users gave Pieris Pharmaceuticals an outperform vote while only 0.00% of users gave FSD Pharma an outperform vote.

CompanyUnderperformOutperform
FSD PharmaOutperform Votes
No Votes
Underperform Votes
1
100.00%
Pieris PharmaceuticalsOutperform Votes
278
61.50%
Underperform Votes
174
38.50%

In the previous week, Pieris Pharmaceuticals had 1 more articles in the media than FSD Pharma. MarketBeat recorded 4 mentions for Pieris Pharmaceuticals and 3 mentions for FSD Pharma. FSD Pharma's average media sentiment score of 0.96 beat Pieris Pharmaceuticals' score of -0.01 indicating that FSD Pharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
FSD Pharma
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Pieris Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Pieris Pharmaceuticals beats FSD Pharma on 9 of the 14 factors compared between the two stocks.

Get FSD Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for HUGE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HUGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HUGE vs. The Competition

MetricFSD PharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$12.80M$6.80B$5.17B$7.96B
Dividend YieldN/A2.72%44.01%3.91%
P/E Ratio-1.2311.68118.4515.56
Price / SalesN/A250.142,367.4177.86
Price / CashN/A35.8536.4531.98
Price / Book0.975.845.754.76
Net Income-$17.90M$140.68M$105.79M$217.17M
7 Day Performance-6.16%1.47%1.39%2.90%
1 Month Performance-31.18%3.72%4.28%6.57%
1 Year Performance-70.19%-1.70%7.71%10.17%

FSD Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PIRS
Pieris Pharmaceuticals
1.0369 of 5 stars
$11.22
-1.0%
N/A-83.1%$13.88M$42.81M-0.5046Analyst Forecast
News Coverage
Gap Up
EDSA
Edesa Biotech
3.2039 of 5 stars
$4.53
+2.3%
$39.00
+760.9%
-30.9%$14.26MN/A0.0016Short Interest ↑
Gap Up
RDHL
RedHill Biopharma
0 of 5 stars
$0.46
-2.1%
N/A-78.8%$13.58M$6.53M0.00113News Coverage
PPBT
Purple Biotech
1.5734 of 5 stars
$0.53
+1.9%
$9.00
+1,611.0%
-70.8%$13.28MN/A-0.5720Upcoming Earnings
KPRX
Kiora Pharmaceuticals
0 of 5 stars
$0.50
-2.0%
N/A-74.0%$13.13MN/A0.0012Gap Up
TNXP
Tonix Pharmaceuticals
2.6105 of 5 stars
$0.18
+5.9%
$5.50
+2,955.6%
-89.6%$15.21M$7.77M-0.02103Gap Up
ERNA
Eterna Therapeutics
0 of 5 stars
$2.35
+9.8%
N/A-24.8%$12.71M$70,000.00-0.588Positive News
Gap Up
High Trading Volume
IMNN
Imunon
2.267 of 5 stars
$1.35
-9.4%
$12.00
+792.2%
+6.1%$12.64M$500,000.00-0.6233Analyst Forecast
Analyst Revision
News Coverage
Gap Up
NRSN
NeuroSense Therapeutics
0 of 5 stars
$1.12
-2.6%
N/A-30.5%$15.31MN/A-1.3518Gap Down
AKTX
Akari Therapeutics
0 of 5 stars
$1.46
-2.0%
N/A-64.2%$11.57MN/A0.009Analyst Forecast
News Coverage
Gap Up

Related Companies and Tools

This page (NASDAQ:HUGE) was last updated on 5/18/2024 by MarketBeat.com Staff

From Our Partners